News
-
A Phase 2 study of inhaled budesonide for the treatment of COVID-19 found that patients who received 800 mcg twice daily plus standard of care within 7 days after first experiencing symptoms had a 90%… Read more . . .
-
According to Protalix BioTherapeutics, the company has signed an agreement with SarcoMed USA giving SarcoMed exclusive worldwide license agreement for Protalix’s PRX-110 inhaled alidornase alfa for the treatment of respiratory diseases including pulmonary sarcoidosis and pulmonary… Read more . . .
-
Hangzhou Chance Pharmaceuticals is paying an undisclosed amount up front, plus milestone payments and royalties, to acquire the rights to develop and commercialize Aerami Therapeutics’ AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension… Read more . . .
-
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform’s biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics… Read more . . .
-
Hovione Technology, a subsidiary of CDMO Hovione, announced that it has been granted a patent on a new method of particle size analysis that provides improved sample preparation for more accurate measurements and better repeatability.… Read more . . .
-
According to Janssen, the company’s Spravato esketamine nasal spray has been approved by the EC as an add-on to oral antidepressants for adult patients with major depressive disorder (MDD) “as acute short term treatment, for… Read more . . .
-
NeuroRx announced that it has initiated a Phase 2/3 clinical trial of nebulized Zyesami aviptadil (RLF-100) for the treatment of severe COVID-19. In August 2020, NeuroRx announced that the FDA had cleared an IND for… Read more . . .
-
AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier… Read more . . .
-
Lindal Group announced that the Chinese National Medical Product Administration’s (NMPA) Center for Drug Evaluation (CDE) has listed the drug master file (DMF) for Lindal’s 20 mm male MDI metering valve as active following review.… Read more . . .
-
Aptar Pharma subsidiary Noble has launched a suite of services for makers of combination products such as OINDPs under the “Human Factors Plus” (HF+) brand. Noble, which was acquired by Aptar Pharma in 2019, makes… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland